Wednesday, October 18, 2017 9:23:00 AM
Oct 2nd PR:
"...today announces that the last patient has completed study treatment in the Company’s Phase 2 clinical trial of Brilacidin for the prevention and treatment of severe Oral Mucositis (OM) in patients undergoing chemoradiation for Head and Neck Cancer. A total of 61 patients were enrolled in the double-blinded study."
Oct 18th PR:
"...is pleased to report that all patients participating in the Phase 2 trial of Brilacidin-OM for the prevention and treatment of Oral Mucositis (OM) in Head and Neck Cancer (HNC) patients have completed therapy and the last patient post-treatment follow-up examination is scheduled for next week."
For beginners the difference between these statements is clear. I was very curious about the Oct 2nd PR and actually reached out to the company because I was confused if that meant the trial was completed and the additional 4 weeks of follow-up was part of that statement: " completed study treatment " So now today made it crystal clear that "...patients have completed therapy and the last patient post-treatment follow-up examination is scheduled for next week."
Now we officially know that dosing was completed and reported on the OCT 2nd PR and the company now informed us that the FINAL patient is to recieve their last follow-up visit via the 4 additional week protocol next week - CLOSING the trial. The PR also states the "...Company will focus on the process of concluding the study, including closing clinical sites and aggregating and analyzing data. Innovation Pharmaceuticals anticipates reporting topline results later this quarter."
The PR also goes into much more detail on the OM market and emphasizes the fact there is no approved PREVENTATIVE drug.
LEO - thank you for the clarification on the study follow-up end.
TIC TOC - this trial will hopefully return 70-90% SOM preventive rates. Which will be the best results this world has ever seen in trial results. I have done extensive research over the last week and I have seen nothing even close to that number. If those numbers come in...we will be granted BreakThrough designation and I believe that will be a milestone payment for a deal that WILL be inked shortly after the results are published publicly.
GET READY FRIENDS/LONGS!!!! We are in for an exciting end of year and 2018!!!!!!!!!!!!!!!!!!
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
FEATURED Cannabix Technologies to Deliver Innovative Breath Logix Alcohol Screening Device to Texas, USA • Jul 29, 2024 9:07 AM
INDEXR AI Merges With Moon Equity Holdings Corp. (MONI), Creating a Leading-edge Technology Company • MONI • Jul 29, 2024 9:59 AM
BNCM AND DELEX UNVEIL POST-MERGER MANAGEMENT PLANS • BNCM • Jul 29, 2024 9:00 AM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM